Loading…
Updated Phase 1 trial results show deep, durable remissions and favorable safety.
Senti Biosciences, Inc. announced on 2025-12-09 Senti Bio announced updated clinical data from its ongoing Phase 1 trial of SENTI-202 in patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML), demonstrating deep, MRD negative, durable complete remissions and a favorable safety profile.
7.6 months median duration of composite Complete Remission. 100% of CRs and ~80%+ of all responses were MRD negative. 6/12 patients at RP2D. 9/18 patients overall. 65% of patients had disease with adverse risk genetics. Median of less than a year from diagnosis. The announcement cited 50% ORR, 42% CR/CRh, median of 2 lines of therapy, and 35% baseline bone marrow blasts.
Senti Biosciences Holdings, Inc. Common Stock has a free float of 9,706,300 shares and 26,290,800 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.